Treatment escalation patterns to start biologics in refractory moderate juvenile dermatomyositis among members of the Childhood Arthritis and Rheumatology Research Alliance.
Matthew A ShermanHanna KimKatelyn BanschbachAmanda BrownHarry L GewanterBianca LangMegan PerronAngela Byun RobinsonJacob SpitznagleCory StinglGrant SyversonHeather O ToryCharles H SpencerStacey E TarvinPublished in: Pediatric rheumatology online journal (2023)
Most respondents favored starting a biologic earlier in disease course after trialing up to two conventional DMARDs, specifically including methotrexate. There was a clear preference for rituximab. However, there remains a dearth of prospective data comparing biologics in refractory JDM. These findings underscore the need for biologic consensus treatment plans (CTPs) for refractory JDM, which will ultimately facilitate comparative effectiveness studies and inform treatment practices.
Keyphrases
- rheumatoid arthritis
- healthcare
- primary care
- clinical trial
- high intensity
- diffuse large b cell lymphoma
- young adults
- combination therapy
- systemic lupus erythematosus
- health insurance
- deep learning
- electronic health record
- artificial intelligence
- disease activity
- juvenile idiopathic arthritis
- idiopathic pulmonary fibrosis
- systemic sclerosis
- clinical practice